We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | 장 마감 후 (AMC) | $-2.23 | — | — | $350.9M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-17.33 | — | — | $137.25M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-19.31 | — | — | $76.81M |
Consensus PT $679.29 · 14 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 14. | Truist Securities | — | 의견 유지 | Buy → Buy | — | Truist Securities: Buy |
| 2026. 05. 08. | Canaccord Genuity | — | 의견 유지 | Buy → Buy | — | Canaccord Genuity: Buy |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| 보고됨 |
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-14.47 | — | — | $14.64M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 225,510 | $118.05B | 0.22% | — | 신규 편입 |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 126,435 | $73.63B | 0.12% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Stored first · Google News · Yahoo Finance (English)
Has Madrigal Pharmaceuticals (MDGL) Cracked the Code for MASH - Kavout
Has Madrigal Pharmaceuticals (MDGL) Cracked the Code for MASH Kavout
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Phase 3 And Real World Rezdiffra MASH Data - simplywall.st
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Phase 3 And Real World Rezdiffra MASH Data simplywall.st
Madrigal Pharmaceuticals (MDGL) Reports Positive Findings on Rezdiffra for MASH Treatment - GuruFocus
Madrigal Pharmaceuticals (MDGL) Reports Positive Findings on Rezdiffra for MASH Treatment GuruFocus
Madrigal Pharmaceuticals Says Data Show Rezdiffra Reduces Cardiovascular, Liver-Related Risks in MASH Patients - Moomoo
Madrigal Pharmaceuticals Says Data Show Rezdiffra Reduces Cardiovascular, Liver-Related Risks in MASH Patients Moomoo
Did New Noninvasive Rezdiffra Data at EASL 2026 Just Shift Madrigal Pharmaceuticals' (MDGL) Investment Narrative? - simplywall.st
Did New Noninvasive Rezdiffra Data at EASL 2026 Just Shift Madrigal Pharmaceuticals' (MDGL) Investment Narrative? simplywall.st